

June 12, 2019
Symbio Pharmaceuticals Limited
Fuminori Yoshida
Representative Director
President & Chief Executive Officer
(Securities Code: 4582)

Notice of Change (Resignation) of Representative Director and Appointment of Corporate Officer

TOKYO, Japan, June 12, 2019 -- Symbio Pharmaceuticals Limited (Headquarters: Tokyo) today announced that the following changes in the positions of representative director (resignation) and appointment of Corporate Officer have been approved by Symbio's Board of Directors.

1. Resignation of Representative Director

(1)

Name	Title
Kazuo Asakawa	Representative Director and Corporate Officer, Executive Vice President and Chief Commercial Officer

(2) Reason and Date of Resignation

Kazuo Asakawa, Representative Director, Executive Vice President and CCO will resign as Representative Director and Corporate Officer for health reasons as of June 30, 2019.

Yoshio Kimura, the newly appointed corporate officer listed in 2 below, will assume Mr. Asakawa's role.

(3) Number of Directors

The Company continues to meet the requirements for number of Directors as provided for by laws and regulations and the Company's Articles of Incorporation after the resignation Mr. Asakawa.

2. Appointment of Corporate Officer

The Company is establishing its own sales organization, to be in place for 2021. The newly appointed corporate officer, Shigeo Kimura, will serve concurrently as Chief Commercial Officer and will be responsible for establishing the sales and marketing organization and overseeing the development of sales activities for the anti-cancer agent TREAKISYM® in Japan.

Shigeo Kimura, Managing Executive Officer, notes that “We will strive to provide more useful information on TREAKISYM® as standard-of-care therapy, and will conduct detailed marketing activities throughout the company to help patients and healthcare professionals.”

Statement from Fuminori Yoshida, Symbio’s President and CEO: “As we expand our business toward our second establishment, we are pleased to welcome Mr. Kimura to our management team. Mr. Kimura has extensive experience in sales, marketing, and commercial operations in Japan and overseas, having worked for many years at Bristol-Myers Squibb Company (BMS), a major U.S. pharmaceutical company that focuses on anti-cancer drugs.”

(1) Newly Appointed Corporate Officer

Name	Title
Shigeo Kimura	Corporate Officer, Managing Executive Officer and Chief Commercial Officer

(2) Date of Appointment

July 1, 2019

(3) Profile of the Corporate Officer

Career Summary	1986	Medical Rep. of Squibb Japan Inc. (currently BMS)
	2007	Marketing Director, Oncology BU, overseeing the launch of dasatinib, a new drug for chronic myelogenous leukemia
	2011	BMS Canada, Senior Product Manager for anti-cancer drugs, dasatinib
	2013	National Sales Director, Cardiovascular Metabolism Immunology BU
	2016	Corporate Officer, Commercial Operations BU Head
	2017	Corporate Officer, Oncology BU Head
	June, 2019	Joined Symbio Pharmaceuticals Limited

[Contact]

Investor Relations

Tel: +81(0)3 5472 1125